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Abstract
Background: In occult hepatitis B viral infection (OBI), the persistence of hepatitis B virus (HBV) DNA is associated
with a lack of hepatitis B surface antigen (HBsAg). To assess the possible role of HBsAg immune escape variants in
OBI patients, variability in the HBV S gene was evaluated for OBI patients as well as chronic HBV infection patients
from the same families.
Methods: We selected 17 HBV DNA-positive/HBsAg-negative patients (OBI group) and 15 HBV DNA- and
HBsAg-positive patients from OBI families (control group). The S gene was amplified and cloned, and at least
15 clones per patient were sequenced and analyzed.
Results: Although the incidence of stop codon mutations within the S region was higher in the OBI group (13.6 %)
than in the control group (1.5 %, P < 0.001), this type of mutation, together with insertion and deletion mutations,
was prevalent in only three OBI patients. In the major hydrophilic region (MHR), a median of 0.75 residues were
altered in every 100 residues for the OBI patients, whereas 0.95 out of 100 residues were changed in the control
group (P = 0.428). Furthermore, some variants that are generally considered immune escape variants, such as
mutations at positions s145, s147, and s123, were only observed in less than 5 % of all the clones sequenced,
in either OBI or control group.
Conclusions: Our data suggest that HBsAg variants may not play a major role in OBI pathogenesis.
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Background
More than 240 million people are chronic carriers of the
hepatitis B virus (HBV) worldwide, posing a serious
public health problem [1, 2]. In the natural course of
HBV infection, virus clearance is classically characterized
by the loss of hepatitis B surface antigen (HBsAg) and
HBV DNA in the serological profile of the patient.
Notably, several reports have described the persistence
of HBV DNA in 0–76.2 % of HBsAg-negative patients
[3–7]. Diagnostically, this phenomenon, named occult
hepatitis B infection (OBI), is defined as the presence of
HBV DNA in the patient’s serum and/or hepatocytes, but
a lack of serum HBsAg [8]. OBI is considered a high po-
tential risk factor for hepatitis, cirrhosis, post transfusion
hepatitis (PTH), and hepatocellular carcinoma (HCC) [3, 8–
11]. While clinical investigation is ongoing, the mechanisms
underlying the presence of HBV DNA and lack of HBsAg
during OBI are not completely understood.
Previous work has implied that OBI development is
possibly related to mutations in the S gene of the
virus, which result in the production of escape mu-
tants that go undetected by the host’s immune system
[12–14]. The HBV S gene (or envelope gene) has three
open reading frames (ORFs), which form three distinct
mRNA moieties that encode the small, medium, and
large HBsAgs. HBsAg mutations at single or multiple
sites in the “α” determinant of the S protein may
emerge as a result of selective pressure. This “α”
dominant epitope of the HBsAg is located from amino
acid 124 to 147 within the major hydrophilic region
(MHR). Some case reports have indicated that there
are a relatively large number of amino acid changes in
this section of the HBsAg in OBI patients [12–18].
Moreover, site-directed mutagenesis experiments, in
which an amino acid was replaced with all other
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possible residues, have confirmed that some amino
acid mutations in the “α” determinant, including
G145R, D144A, P142S, Q129H, and M133L, could
lead to decreased HBsAg binding and HBsAg test fail-
ure [18–21]. However, no specific S gene mutations
previously studied have been clinically detected in a
large enough number of OBI cases to indicate caus-
ation [22–26]. We believe that the merit of these
former studies is limited by the small number of
clones or patients analyzed and the fact that the preva-
lence of naturally occurring mutations in the “α”
determinant is unknown, particularly in OBI patients.
In this study, we assessed the role of HBsAg immune
escape variant selection in OBI by evaluating the level of
variation present in the HBV S gene in a large number
of OBI patients as well as patients with chronic HBV
from the same families.
Results
Clustering of 15 OBI-affected families
A total of 747 HBsAg-negative sera samples were
collected from 265 families in which at least one family
member had a chronic HBV infection. Of these samples,
60 (8.0 %) were identified as OBI. In order to explore the
mechanisms underlying OBI, we investigated 17 of the
patients diagnosed with OBI from 15 families (F1–F15)
which also include a member with chronic HBV infection.
Due to death of a family member and other unforeseen
events, we were unable to obtain serum samples from
some members of these 15 families. Of the samples col-
lected from these families, 44 individuals were negative for
HBsAg, among which 17 were diagnosed as OBI. Only 5
of these families (F2, F3, F10, F11, and F15) had 2 mem-
bers with chronic HBV infection, whereas 2 families had 2
OBI patients. The relationship between a patient with
chronic HBV infection and a patient with OBI could be ei-
ther parent/child or sibling (Fig. 1). Notably, most of the
OBI patients did not manifest any clinical symptoms, with
the exception of one patient who presented with fatigue,
loss of appetite, and elevated alanine aminotransferase
(ALT) in multiple laboratory examinations. This patient
was free of human immunodeficiency virus (HIV) and
hepatitis C virus (HCV) infections, adiposis hepatica,
drug-induced hepatitis, and autoimmune hepatitis, and
refused to accept experimental anti-viral therapy. Among
patients in the control group, 10 were diagnosed with
chronic HBV infection, whereas 3 were diagnosed with
cirrhosis and 2 appeared to be asymptomatic HBV carriers
(Table 1). Notably, the OBI and control groups were com-
parable with regard to gender bias (10 male patients were
present in each group, P = 0.647) and median age (34 years
Fig. 1 Distribution of OBI and control patients in 15 families included in this study. Symbols: square, male; circle, female; O, OBI patient; C, control
patient; CHI, chronic HBV infection patient; ND, not detected. Each family was assigned an ID number. If a family had two OBI or control patients,
a, b were used to specify them respectively
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in both groups, P = 0.395) (Table 1). All patients were
negative for HCV and HIV antibodies.
Virological characteristics
As shown in Table 1, HBV genotype distributions were
heterogeneous in both groups, and genotype B/C co-
infection was also observed (5 and 3 patients in the OBI
group and control group, respectively, P = 0.539). In fact,
12 patients with OBI (70.6 %) had the same genotype as
their family members with chronic HBV infection.
Among the other 5 OBI patients, the majority of clones
(17, 18, 15 out of 19, 20, and 19 clones) were also ob-
served to be genotypically similar to their family mem-
bers with chronic HBV infection. In the OBI group, all
patients were negative for HBsAg and HBV e antigen
(HBeAg). At the same time, the HBV DNA titers were
less than 1000 copies/ml in all patients, whereas the
levels of HBsAg-specific antibodies (anti-HBs) in pa-
tients with OBI were rather high, with 11 patients having
an anti-HB titer greater than 10 IU/l and a median titer
of 49 mIU/ml. In contrast, the frequency of OBI patients
positive for HBeAg- and HBV core-specific antibodies
Table 1 Main patient characteristics
Family Patient Sex Age Diagnosis Kinship Serological markers Viral load ALT Genotype
years HBsAg Anti-HBs HBeAg Anti-HBe Anti-HBc (log 10 copies/ml) U/L (Major/Minor)
F1 C1 F 30 CHB - + <10 - + + <3.0 47 C/B
O1 M 57 OBI Father - 175 - - - <3.0 37 C
F2 C2 F 69 LC - + <10 - + + 5.9 36 C
O2 F 39 OBI Daughter - 31 - - + <3.0 15 C
F3 C3 F 52 CHB - + <10 + - + 3.1 76 C
O3 M 27 OBI Son - >1000 - - - <3.0 27 B/C
F4 C4 M 19 CHB - + <10 - + + <3.0 143 C
O4 F 49 OBI Mother - 59 - - - <3.0 16 C
F5 C5 M 32 ASC - + <10 - - + <3.0 34 C
O5a F 10 OBI Daughter - <10 - - - <3.0 11 C
O5b M 5 OBI Son - 49 - - - <3.0 10 C
F6 C6 M 48 CHB - + <10 + - + 4.1 75 B/C
O6 M 46 OBI Brother - <10 - + + <3.0 16 C
F7 C7 M 31 CHB - + <10 + - + 5.3 54 C
O7 M 29 OBI Brother - 52 - - + <3.0 9 C
F8 C8 M 19 CHB - + <10 - + + <3.0 85 C
O8 F 44 OBI Mother - <10 - - - <3.0 27 C/B
F9 C9 M 36 CHB - + <10 + - + 5.7 105 C
O9 M 9 OBI Son - >1000 - - - <3.0 13 C
F10 C10 M 56 LC - + <10 - + + <3.0 68 C
O10 F 19 OBI Daughter - <10 - - + <3.0 194 C
F11 C11 F 22 CHB - + <10 - - + 5.1 59 C
O11 M 44 OBI Father - 56 - - - <3.0 19 C
F12 C12 F 34 ASC - + <10 - - + 4.0 15 C
O12 M 14 OBI Son - 255 - - - <3.0 15 C
F13 C13 M 35 CHB - + <10 + - + <3.0 1678 B/C
O13a F 40 OBI Sister - <10 - - - <3.0 25 B/C
O13b M 34 OBI Brother - <10 - - - <3.0 18 B/C
F14 C14 M 18 CHB - + <10 + - + 6.3 316 C
O14 F 23 OBI Sister - 39 - - + <3.0 9 C/B
F15 C15 M 59 LC - + <10 - - + <3.0 59 C
O15 M 36 OBI Son - 132 - - + <3.0 34 C
C control, O occult hepatitis B infection, F female, M male, ASC asymptomatic HBV carrier, CHB chronic hepatitis B, LC liver cirrhosis, ALT Alanine aminotransferase,
O5a and O5b come from one family, O13a and O13b come from one family
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(anti-HBe, 1 in 17 and anti-HBc, 6 in 17) was lower than
that found in the control group (5 in 15, P = 0.047 and
15 in 15, P < 0.001, respectively). The patients in the
control group also had a higher viral load, with a median
of 3.1 log10 copies/ml (range, < 3 to 6.1, P < 0.001), as
well as higher ALT levels (median: 16 and 68 U/L for
the OBI and control groups, respectively, P < 0.001).
Surface region mutations
A cloning-sequencing approach was used to study the
entire S gene sequence for patients from each group. In
order to standardize our comparison, we selected two
standard reference sequences: genotype B (GQ205440)
and genotype C (GQ205441), both of which are found in
the Chinese population [27].
Clones from 10 patients in the OBI group and 5
patients in the control group harbored termination,
insertion, or deletion (TID) mutations in the HBV S
gene. Amino acids variations in the OBI group and the
control group were compared (Table 2, Fig. 2). Among
these mutations, some nucleotide insertions or deletions
caused reading frame shifts in the S protein of OBI pa-
tients (5 clones) as well as in the control group (1 clone).
The frequency of stop codon mutations in the OBI
group (13.6 %) was significantly higher than that found
in the control group (1.5 %, P < 0.001). Further, the inci-
dence of insertion or deletion mutations in patients in
the OBI group (4.4 %) was also higher than that in the
control group (1.9 %), although this difference was not
statistically significant (P = 0.084). Notably, 3 patients
with OBI had TID mutations in more than 50 % of the
clones that contained sequences encoding the S protein.
In these patients, the antigenicity of HBsAg was likely to
be altered, potentially losing its ability to induce anti-
body production entirely. Interestingly, the presence of
mutated clones always appeared to be associated with
the detection of at least one wild-type HBV clone in
each patient, and the same patient could be infected
with a mixture of HBV strains incorporating a variety of
residue changes in the S protein.
Table 2 Distribution of stop codon, insertion, deletion and reading frame shift mutations in the full-length S protein
OBI group Control group
Patient Genotype Na Mutationb Type Site (aa) Notec Patient Genotype N Mutationa Type Site (aa) Noteb
O1 C 3 TGT→ TGA Stop 69 C1 B 1 TTG→ TAG Stop 209
C 4 TGG→ TGA Stop 182
C 3 AGCACGGGACCA Deletion 117-120 STGP
O2 C 1 TTT Deletion 220 F
O3 B 1 TGG→ TAG Stop 35
O5a C 2 TGG→ TAG Stop 163
C 1 Add “T” nt638 Shift 213
O6 C 1 TTA→ TGA Stop 217 C6 B 1 Miss “G” nt606 Shift 203
O8 B 1 Miss “G” nt54 Shift 20
C 1 Add “T” nt607 Shift 203
C 1 Miss “G” nt54 Shift 20
C 1 Miss “T” nt240 Shift 80
O9 C 2 TTA→ TAA Stop 216
C 4 ACC Insert 124-125 T
C10 C 3 AACAACAAC Insert 116-117 TTT
C 2 TGG→ TAG Stop 195
O11 C 8 TTA→ TAA Stop 216 C11 C 1 AACAACAAC Insert 116-117 TTT
C 1 AACAACAAC Insert 117-118 TTT
O13a B 8 TGT→ TGA Stop 107 C13 B 1 CAG→ TAG Stop 30
C 7 TTA→ TAA Stop 216
O15 C 6 TTA→ TAA Stop 216
Shift reading frame shift, Insert insertional mutation, Deletion deletion mutation, Stop stop codon mutation
a the number of clones with stop codon, insertion, deletion or reading frame shift mutations in the full-length S protein
b the different types of nucleotide variation, e.g. TGT→ TGA indicate the nucleotide sequence change into TGA from TGT; “AGCACGGGACCA” et al. is the
nucleotide sequence of insertions or deletions; Add “T” nt638 indicate to add a base”T” after nt638 of S gene; Miss “G” nt54 indicate to miss a base”G” after nt54
of S gene
c the amino acid sequence of insertions or deletions
b, c Reference sequence: genotype B (GQ205440), genotype C (GQ205441)
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Although TID and frameshift mutations appear to
occur in both OBI and control patients in each family,
the site and type of the mutations varied for each indi-
vidual patient. TID mutations were less frequently found
in clones from patients in the control group. For in-
stance, TID mutants were found in only 1 clone from
control patients from families 1, 6, 11, and 13. Further-
more, in family 10, no TID mutant was found in the
OBI patient, but insertion or termination mutations
existed in 5 clones (26.3 %) from the control patients. In
the families with 2 OBI patients (F5, F13), TID muta-
tions were found in only 1 of the OBI patients (O5a,
O13a), but not the other (O5b, O13b), and these muta-
tions were not observed in the control patient (C5, C13)
in either family (Table 2).
Statistical analysis of mutations occurring in the OBI and
control groups
A comparison of all clone sequences (excluding clones
that incorporated TID mutations) from each patient was
performed. The clone sequences derived from individual
patients were then compared to a consensus sequence of
the same genotype to identify uncommon residues. The
percentages of amino acid residue substitutions were
also compared between the OBI group and the control
group. In the 17 OBI patients, most clones were highly
homologous to those from their HBV-infected family
members. The 226 amino acids of the S protein can be
divided into three regions: the N-terminal region (1 to
99), the MHR (100 to 169; which includes the “α”
determinant from 124 to 147), and the C-terminal
region (170 to 226). Our analysis indicates that the dis-
tribution of amino acid substitutions in the S protein
was heterogeneous, and the frequency/accumulation of
these changes in most areas of the protein was similar
between the two groups (P = 0.461) (Table 3). In all pa-
tients, the C-terminal region of the protein appeared to
be more variable in terms of residue substitution (3.95/
100 amino acids in the OBI group and 3.79/100 amino
acids in the control group) compared to the N-terminal
region or the MHR (Table 3). In the MHR, a median of
0.75 residues were altered in every 100 residues for the
OBI patients, and 0.95 out of 100 residues were changed
in the control group (P = 0.428). Notably, although mul-
tiple mutations were observed within the “α” determin-
ant in both groups (36 clones, 13.8 % in the OBI group
and 52 clones, 20.1 % in the control group), the residue
changes in OBI group patients within the “α” determin-
ant was less frequent than that in control group patients
(averaging 0.188 and 0.297 amino acid mutations per
clone, respectively, P = 0.049) (Fig. 3a). However, the
mutation frequency in this site was not significantly dif-
ferent between the OBI group (0.69 mutated residues
per 100 amino acids) and the control group (1.16 mu-
tated residues per 100 amino acids, P = 0.307) (Table 3).
Thus, we doubt that this difference in the accumulation
of mutated residues in the “α” determinant between the
OBI and HBV groups would be enough to significantly
alter the immunogenicity of the S protein.
Important immune escape mutations
Fragment analysis of sequences approximately 7–10
amino acids long revealed no significant differences in
the amino acid substitution rate between the OBI and
control patients in the majority of regions. Moreover,
while the nucleotide substitution rate within amino acids
130 to 139, which belong to the MHR, in OBI patients
(0.27) was significantly lower than that in the control
group (0.69, P = 0.027, Fig. 3b), the overall percentage of
amino acid substitutions within the MHR of individual
patients was similar between the two groups (Table 4).
Most of the sequenced clones also had a high degree
of similarity to their appropriate reference sequences
(genotype B or C). More than 10 % of the sequenced
clones either had amino acid substitutions at s127 and
s161 if it belonged to genotype B or at s110 and s126 if
it belonged to genotype C, and the incidence of amino
acid substitution at s110, s126, s127, and s161 in the
OBI group was similar to or lower than that observed in
the control group (P = 0.944, 0.417, 0.357, and 0.018,
respectively). Substitutions at several positions, including
s110, s113, s126, s143, s160, and s161, appeared to be
genotype-specific (Table 4) [27, 28]. Notably, the muta-
tions at s110, s126, and s161 have been considered high-
frequency amino acid substitutions and were found in
both the OBI and HBV groups, but the clinical signifi-
cance of these mutations still needs to be clarified. In
terms of immunogenicity, mutations typically associated
Fig. 2 Frequencies of clones with stop codon, insertion, deletion and
reading frame shift mutations in the full-length S gene for OBI group
(black bars) and Control group (white bars). Statistical significance was
calculated by using the ANOVA test. *, P < 0.05
Zhang et al. Virology Journal  (2016) 13:10 Page 5 of 11
with altered S protein function are known to occur at
positions s123, s145, and s147. However, mutations in
these positions were found in only 1, 2, and 2 clones in
the OBI group, respectively.
Discussion
Recently, several studies investigating the prevalence of
OBI among blood donors from various regions of the
world demonstrated that 0 to 2.87 % of the donors had
OBI (reviewed by Assar et al.) [3]. The prevalence of OBI
has also been found to be significantly higher in leukemia
and hemodialysis patients [5, 29, 30]. Thus, the detection
and analysis of OBI is essential for proper diagnosis. A few
factors have been suggested to affect the detection of OBI,
including the sensitivity and reliability of the technology
used (e.g., the ELISA assay for detection of HBsAg vs.
PCR analysis), the size of the serum sample pool, and the
variation in HBV genotype in different regions/popula-
tions [31–33]. In the present study, we took various
measures to address these technical issues. For example,
we tested each sample using two different diagnostic kits
(Kehua and Abbott) that are widely used in China. This
allowed us to minimize the incidence of false negative
results. Since our quantitative assay indicated that the
level of HBV DNA in OBI patients was very low, we
further performed nested PCRs for the S, C, and X regions
using primer sets specific for these regions. By stipulating
that samples must be positive for at least two of these re-
gions to be considered HBV DNA-positive, we signifi-
cantly reduced the chance for false positive results. These
procedures revealed that the prevalence of OBI in families
with a history of HBV infection was approximately 8.0 %,
a result that is corroborated by several previous clinical
investigations [4, 6, 7].
After eliminating technical bias, we sought to eluci-
date the underlying mechanisms involved in OBI
pathogenesis, which have been suggested to be related
to genetic variation, HBV reproduction levels, gene
integration, suppressed expression and secretion of
HBsAg, co-infection with HCV, host genetic or im-
mune status, or any combination of these or other
phenomena. Numerous studies have shown that amino
acid substitutions or variations in the S gene not only
occur in OBI patients, but may also be present in
chronic HBV infection patients [34–36]. However,
most studies in the current literature on S gene muta-
tions in OBI patients are limited by various problems
such as lack of a control group, simply using patients
with chronic HBV infection in the general population
as the control, small sample size, and/or retrieving
sequence information simply by sequencing the PCR
products without a cloning step. Thus, in order to
Table 3 Distribution of amino acid changes in the full-length S protein and its different regions
OBI
group
No. of residue changes/100 aaa Control
group
No. of residue changes/100 aaa
aa 1–226 aa 1–99 aa 100–169 aa 124–147 aa 170–226 aa 1–226 aa 1–99 aa 100–169 aa 124–147 aa 170–226
O1 2.41 2.24 0.79 1.85 4.68 C1 1.70 1.12 0.83 1.54 3.79
O2 1.37 1.01 0.75 0.44 2.77 C2 1.71 0.38 0.89 0.00 5.04
O3 1.43 1.07 0.59 0.74 3.10 C3 1.51 1.17 0.23 0.00 3.69
O4 1.92 1.57 0.79 0.69 3.90 C4 1.86 1.48 0.86 0.56 3.74
O5a 2.16 1.90 1.60 1.47 3.30 C5 1.11 0.90 0.24 0.23 2.53
O5b 1.42 1.01 0.14 0.00 3.68
O6 2.16 1.31 1.09 1.23 4.95 C6 2.47 2.02 2.86 4.17 2.77
O7 1.13 0.39 0.56 0.00 3.12 C7 2.26 2.50 1.18 2.45 3.20
O8 1.49 1.08 0.31 0.00 3.63 C8 2.29 2.13 1.19 1.16 3.90
O9 1.73 0.81 0.57 0.00 4.74 C9 1.99 0.86 2.00 2.29 3.95
O10 1.93 0.48 1.68 0.74 4.75 C10 1.77 1.01 1.02 1.49 4.01
O11 1.37 0.40 1.29 2.08 3.16 C11 1.96 0.38 1.70 1.30 5.04
O12 1.43 0.56 0.56 0.00 4.00 C12 1.62 0.67 1.81 2.22 3.04
O13a 2.21 1.11 1.64 1.04 4.82 C13 1.23 0.79 0.24 0.23 3.22
O13b 1.47 0.67 0.48 0.00 4.09
O14 1.44 0.51 0.71 0.00 3.95 C14 1.43 0.77 0.34 0.00 3.92
O15 2.96 1.55 2.86 3.21 5.53 C15 2.26 1.68 0.95 0.00 4.87
Median 1.49 1.01 0.75 0.69 3.95 Median 1.77 1.01 0.95 1.16 3.79
P-Value 0.461 0.623 0.428 0.307 0.546
aa 1–226 full-length region, aa 1–99N-terminal region, aa 100–169 MHR antigenic loops, aa 124–147 “α” determinant, aa 170–226 C-terminal region; areference
sequence: genotype B (GQ205440), genotype C (GQ205441)
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Fig. 3 (See legend on next page.)
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further clarify the role of S gene genetic variation in
OBI, we investigated the prevalence of OBI in Chinese
families with HBV infection. The S gene from family
members with chronic HBV infection or OBI was then
amplified, cloned, and sequenced. In order to improve
reliability and comparability, HBsAg-positive patients
from families with OBI were selected as controls be-
cause they were likely to share the same source of
infection as the OBI patients in addition to having
similar living environments and genetic background,
enabling us to provide a more meaningful comparison
between the OBI group and the control group. These
OBI patients and their corresponding family members
in the control group could be parent–child or sibling
relationships, but the differences in age and gender
between the two groups were minimal. Our analysis
showed that, most clones from 15 OBI patients were
highly homologous to those from their HBV-infected
family members, indicating that it is likely that most
OBI patients share the same sources of infection with
their control family members (data not shown).
Consistent with previous studies, the levels of HBV
DNA detected in all of the OBI patients were lower than
1000 copies/ml, whereas some of them were negative for
all other serological markers and antibodies. Some pa-
tients were also found to have abnormal liver function.
Further, eight patients in both the OBI and control groups
were infected with a medley of HBV genotypes, including
B and C variants. Sequencing of the PCR products was
performed twice for each sample in order to exclude po-
tential single-sample contamination. Double peaks present
at some genotype-specific sites suggest the existence of
co-infection by different genotypes. Although mixed HBV
infection was more common in the OBI group than in the
control group, this difference was not statistically signifi-
cant, indicating that mixed genotype HBV infection does
not play a major role in OBI pathogenesis.
In this study, reliability in our methodology and re-
sults was also enhanced by using appropriate reference
strains. In most previous studies investigating S gene
variation, researchers utilized reference strains that did
not necessarily correspond to the local strains in their
respective areas [34, 35]. Instead, they used sequences
that had obvious differences from the local HBV geno-
type reference strain, an error that we believe likely
resulted in an increase in the detected number of
amino acid substitutions in both OBI- and HBsAg-
positive patients. This would likely affect the subse-
quent statistical analysis and could potentially generate
bias in the analysis. Therefore, in the present study
we chose the genotype B and genotype C reference
strains from China, which largely decreased the num-
ber of amino acid substitutions detected in the S gene
in both groups.
(See figure on previous page.)
Fig. 3 a. Numbers of residue changes in clones from OBI group and Control group patients within the “α” determinant of the MHR. The numbers
for the 260 clones (circles) in OBI group and the 259 clones (squares) in Control group are distributed according to the numbers of residue
changes in the “α” determinant. Lines and numbers above them in parentheses, means of amino acid mutation/clone in the “α” determinant;
numbers on the right side of circles or squares, numbers of clones. Statistical significance was calculated using a Mann–Whitney test. b.
Frequencies of residue substitutions within the S protein in isolated clones from HBsAg- negative patients (OBI group, black bars, n = 17) and
HBsAg- positive patients (Control group, white bars, n = 15), analyzed in intervals of 10 amino acids each. Each bar represents the percentage of
mutated residues for all clones at each interval of 10 amino acids per group. *, P < 0.05
Table 4 Comparison of the amino acid sequence in MHR of HBsAg between OBI group and control group
The amino acid sequence derived from each clone was compared to a reference sequence from the same genotype chosen in order to standardize our
comparison. The locations of residues with regard to the MHR are given at the top of each group and gray shading region belong to “ɑ” determinant.
Each reference or substituted amino acid is represented in the aa or S line, the number of clones with the change are indicated in the N line. red letter indicates
HBV genotype-specific amino acid. Reference sequence: genotype B (GQ205440), genotype C (GQ205441)
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Furthermore, it is likely that the presence of stop
codon mutations as well as deletion and insertion mu-
tations in both groups can affect expression, secretion,
and antigenicity of the HBsAg. In order to investigate
the biological significance of these mutations, we
cloned and sequenced the S gene from patients in both
groups. Notably, stop codon mutations and deletion/in-
sertion mutations were more common in the OBI
group (13.6 % and 4.4 %, respectively) than in the con-
trol group (1.5 % and 1.9 %, respectively). However,
these mutations were found in only 18.0 % of the clones
sequenced for the OBI group and existed as the domin-
ant variations in only 3 of the OBI patients investigated.
Therefore, we suspect that these mutations only affect
HBsAg expression, secretion, and/or antigenicity in a
minority of OBI patients.
For the clones in both groups without any TID muta-
tions, we performed a sequential sequence analysis for
every 9–10 amino acids of the S gene. Our data indi-
cated that the frequency of amino acid changes in resi-
dues 1–9, 180–189, and 220–226 of HBsAg was higher
than other regions (more than 4 per 100 amino acids) in
both groups, and there were no statistically significant
differences between the OBI patients and the control pa-
tients for the majority of the gene. However, compared
to the controls, residues 170–179 in the OBI group were
more highly mutated than those in the control patients.
It is also worth noting that mutations in these regions
have not been previously associated with OBI pathogen-
esis. Alternatively, the frequencies of amino acid changes
in the N-terminal, C-terminal, and MHR, including the
“α” determinant area, of the S gene in the OBI group
were not significantly different from those in the control
group. In fact, single point mutations in the MHR and
“α” determinant that could affect the antigenicity of
HBsAg, such as G145R, Q129N, D144A, and T123N,
were rarely found in our sequenced clones from either
group, indicating that point mutations in the HBsAg S
gene may play little, if any, role in OBI.
Although the low viral load of the OBI patients included
in this study made it difficult to carry out whole genome
cloning to fully investigate the role of mutations present
in regions outside the S gene [37], we believe additional
study using similar procedures will help advance our
understanding of OBI. For example, the commercial
Abbott kit was able to detect some mutations within the S
gene, such as G145R, etc., and it may be a useful tool to
exclude some “occult HBV infection” patients with G145R
mutation in this study [38, 39]. Using this and similar
tools as well as proper controls and reference sequences,
we hope to elucidate the mechanisms responsible for
HBsAg negativity in OBI patients as a better understand-
ing of OBI will ultimately lead to more accurate diagnosis
of and better treatment for chronic HBV infection.
Conclusions
In summary, cloning of the S gene in OBI patients and
their HBsAg-positive family members revealed that the
total number of amino acid substitutions or variations
in the S protein was not significantly altered in the ma-
jority of clones isolated from OBI patients, indicating




From March 2010 to July 2014, we collected 747
HBsAg-negative sera samples from 265 families in which
at least one family member had a history of chronic
HBV infection. These samples were collected at 14 dif-
ferent hospitals in China. A total of 17 cases of occult
HBV infection (OBI group) and 15 cases of chronic
HBV infection (control group) from the same families
were included in this study. The study protocol was
reviewed and approved by the Ethics Committee of the
First Affiliated Hospital, Anhui Medical University (PJ
20-14-05-12), and informed consent was obtained from
each patient prior to inclusion in the study.
The blood samples collected from each patient were
centrifuged at 950 × g for 5 min. The isolated serum
from each sample was used for serological tests within
4 h. The rest of the samples were then stored at −80 °C.
Detection of HBV serological markers
HBsAg, anti-HBs, HBeAg, anti-HBe, and anti-HBc were
detected with an enzyme-linked immunosorbant assay
(ELISA) using a diagnostic kit (Kehua Biotechnology,
Shanghai, China). Sera samples from patients with OBI
were retested for the presence of HBsAg and anti-HBs
by using a standard commercially available microparti-
cle enzyme immunoassay (AxSYM assay; Abbott,
Wiesbaden, Germany) in order to confirm the absence
of HBsAg in their sera. Patients were also tested for
HIV and HCV using ELISA assays with diagnostic kits
(Kehua Biotechnology, Shanghai, China). Serum HBV-
DNA levels were measured using a TaqMan real-time
PCR assay (Zhijiang Biotechnology, Shanghai, China)
with a lower limit of detection of 1000 copies/ml.
Extraction and amplification of the HBV genome
DNA was extracted from 200 μl of each patient’s serum
by using a phenol-chloroform extraction method, and
suspended in 20 μl of water. Nested PCR was performed
using primers specific for the S, C, and X regions of the
HBV genome by following the methods described by
Zhang et al. [40, 41], and the detection sensitivity ranged
from 20 to 50 copies/ml.
Nested PCR was also performed using specific primers
targeting the full length small S gene. The primers were
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designed according to previously reported reference se-
quences (GenBank: GQ205440, GQ205441) for strains
found in Chinese patients [27]. The primer sequences used
in this experiment were: 5’-CTGGTGGCTCCAGTTC-3’
and 5’-CTT(G/A)TAAGTTGGCGAG-3’ (for the first
round of PCR), 5’-ACGGAATTCG(T/C)ACCGAA(C/
T)ATGGAGA(A/G)-3’ and 5’-GCACTGCAGTTAAATG-
TAT(A/G)CCCAAAG-3’ (for the second round). The first
round of PCR was carried out in a final volume of 25 μl
containing 2.5 μl of 10× PCR buffer which contained
15 mM MgCl2, 1 μl of 10 mM dNTP, 1 μl of each primer
(10 mM), 2.5 units of Taq polymerase (Takara, Dalian,
China), and 5 μl of DNA template. The cycling conditions
were initiated with denaturation at 94 °C for 3 min,
followed by 30 cycles of 94 °C for 45 s, 55 °C for 60 s, and
72 °C for 90 s. The second round of PCR was carried out
using 5 μl of the PCR product obtained in the first round
and 1 μl of each primer (10 mM). The cycling conditions
were initiated with denaturation at 94 °C for 3 min,
followed by 30 cycles of 94 °C for 45 s, 57 °C for
60 s, and 72 °C for 90 s. A final extension step was
performed for 7 min at 72 °C. The amplification
products (10 μl of each) were analyzed by electro-
phoresis on a 3.5 % agarose gel stained with ethidium
bromide and observed under ultraviolet light with an
Image analysis system (Tanon, Shanghai, China). The
detection sensitivity was determined to be 50 copies/
ml by using control plasmid pHBV1.3, which contains
the full-length HBV genome. The size of the PCR
product was calculated using the Tanon software
(Tanon, Shanghai, China) to analyze the migration of
PCR product and the DL2000 DNA marker (Takara,
Dalian, China) on the agarose gel. In doing so, it ap-
pears that the product was approximately 700 bps.
Cloning and sequencing of the S gene
Following PCR amplification and electrophoresis, the
small S gene PCR products were recovered from the
agarose gel, purified with the QIAquick Gel Extraction
Kit (QIAGEN, Dusseldorf, Germany), and cloned
using a pMD18-T cloning kit (Takara, Dalian, China).
The recombinant plasmids were then isolated with a
DNA extraction kit (Takara, Dalian, China), and clonal
sequencing (Sangon, Shanghai, China) was performed
using an automated DNA sequencer (ABI3730). Align-
ment and multiple comparisons of the resulting HBV
sequences to two GenBank reference sequences (geno-
type B: GQ205440 and genotype C: GQ205441) were
performed using Primer5.0 software (http://www.pre-
mierbiosoft.com/primerdesign/index.html) [27]. Geno-
typing of HBV was then performed by phylogenetically
analyzing the S gene using sequences from the data-
base [42].
Statistical analysis
Statistical analyses were performed using the SPSS statistics
package version 17.0 (SPSS Inc., Chicago, USA). The rate
comparison was made using the chi-square criterion. Stu-
dent’s t-test and nonparametric test were used to compare
difference between groups, where appropriate. Differences
corresponding to a P < 0.05 were considered statistically
significant in all comparisons.
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